Page 56 - JCTR-11-2

Journal of Clinical and
Translational Research CMV secular trends and race

1998;65(4):515-523. doi: 10.1186/1471-2369-15-171
doi: 10.1097/00007890-199802270-00011 20. White NH, Yow MD, Demmler GJ, et al. Prevalence of
10. Podder H, Podbielski J, Hussein I, Katz S, Van Buren C, cytomegalovirus antibody in subjects between the ages of 6
Kahan BD. Sirolimus improves the two-year outcome of and 22 years. J Infect Dis. 1989l;159(6):1013-1017.
renal allografts in African-American patients. Transpl Int. doi: 10.1093/infdis/159.6.1013
2001;14(3):135-142.
21. Helanterä I, Kyllönen L, Lautenschlager I, Salmela K,
doi: 10.1007/s001470100315 Koskinen P. Primary CMV infections are common in
11. Weber M, Deng S, Arenas J, et al. Decreased rejection kidney transplant recipients after 6 months valganciclovir
episodes in African-American renal transplant recipients prophylaxis. Am J Transplant. 2010;10(9):2026-2032.
receiving mycophenolate mofetil/tacrolimus therapy. doi: 10.1111/j.1600-6143.2010.03225.x
Transplant Proc. 1997;29(8):3669-3670.
22. Staras SA, Dollard SC, Radford KW, Flanders WD,
doi: 10.1016/s0041-1345(97)01067-1 Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus
12. Branson RD, Davis K Jr., Butler KL. African Americans’ infection in the United States, 1988-1994. Clin Infect Dis.
participation in clinical research: Importance, barriers, and 2006;43(9):1143-1151.
solutions. Am J Surg. 2007;193(1):32-39, discussion 40. doi: 10.1086/508173
doi: 10.1016/j.amjsurg.2005.11.007 23. Isaacs RB, Nock SL, Spencer CE, et al. Racial disparities in renal
13. Lantos PM, Permar SR, Hoffman K, Swamy GK. The transplant outcomes. Am J Kidney Dis. 1999;34(4):706-712.
excess burden of cytomegalovirus in African American doi: 10.1016/S0272-6386(99)70397-5
communities: A geospatial analysis. Open Forum Infect Dis.
2015;2(4):ofv180. 24. Williams A, Richardson C, McCready J, et al. Black ethnicity
is not a risk factor for mortality or graft loss after kidney
doi: 10.1093/ofid/ofv180 transplant in the United Kingdom. Exp Clin Transplant.
14. Zuhair M, Smit GSA, Wallis G, et al. Estimation of the 2018;16(6):682-689.
worldwide seroprevalence of cytomegalovirus: A systematic doi: 10.6002/ect.2018.0241
review and meta-analysis. Rev Med Virol. 2019;29(3):e2034.
25. Harding K, Mersha TB, Pham PT, et al. Health disparities
doi: 10.1002/rmv.2034 in kidney transplantation for African Americans. Am J
15. Gruber SA, Garnick J, Morawski K, et al. Cytomegalovirus Nephrol. 2017;46(2):165-175.
prophylaxis with valganciclovir in African-American renal doi: 10.1159/000479480
allograft recipients based on donor/recipient serostatus. Clin
Transplant. 2005;19(2):273-278. 26. Limaye AP, Budde K, Humar A, et al. Letermovir vs
valganciclovir for prophylaxis of cytomegalovirus in high-
doi: 10.1111/j.1399-0012.2005.00337.x risk kidney transplant recipients: A randomized clinical
16. Taber DJ, Gebregziabher M, Hunt KJ, et al. Twenty years trial. JAMA. 2023;330(1):33-42.
of evolving trends in racial disparities for adult kidney doi: 10.1001/jama.2023.9106
transplant recipients. Kidney Int. 2016;90(4):878-887.
27. Raglow Z, Kaul DR. A new antiviral option for
doi: 10.1016/j.kint.2016.06.029
cytomegalovirus prevention after kidney transplant. JAMA.
17. Purnell TS, Luo X, Kucirka LM, et al. Reduced racial 2023;330(1):27-29.
disparity in kidney transplant outcomes in the United doi: 10.1001/jama.2023.9100
States from 1990 to 2012. J Am Soc Nephrol. 2016;27(8):
2511-2518. 28. Brum S, Nolasco F, Sousa J, et al. Leukopenia in kidney
transplant patients with the association of valganciclovir
doi: 10.1681/ASN.2015030293
and mycophenolate mofetil. Transplant Proc. 2008;40(3):
18. Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2017 annual 752-754.
data report: Kidney. Am J Transplant. 2019;19(Suppl 2): doi: 10.1016/j.transproceed.2008.02.048
19-123.
29. Lentine KL, Smith JM, Miller JM, et al. OPTN/SRTR
doi: 10.1111/ajt.15274
2021 annual data report: Kidney. Am J Transplant.
19. Patzer RE, Gander J, Sauls L, et al. The RaDIANT community 2023;23(2 Suppl 1):S21-S120.
study protocol: Community-based participatory research doi: 10.1016/j.ajt.2023.02.004
for reducing disparities in access to kidney transplantation.
BMC Nephrol. 2014;15:171. 30. Moayedi Y, Fan CS, Miller RJ. Gene expression profiling and

Volume 11 Issue 2 (2025) 50 doi: 10.36922/jctr.24.00067